During the first two months of the corona pandemic, researchers at the Department of Clinical Microbiology at Umeå University developed a sensitive test of SARS-CoV-2 antibodies, to determine whether a person had covid-19. In May 2020, the antibody test was validated for clinical use in Region Västerbotten, Sweden. This was the start of the company Xerum.
Xerum’s antibody test is optimized for self-sampling. Xerum’s team has an extensive background in research in immunology and infectious diseases and has broad experience conducting large-scale antibody studies.
The goal of the UBI project is to broaden the scope and develop tests for other infections.
